Archives

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

B SUZHOU, China, May 5, 2026 /PRNewswire/ — BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as ” BrightGene Bio-Medical” or “the Company”) announced that… Login to continue reading Login…

Read MoreBGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

Global Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

B GMCL’s IPO Opportunities Fund targets investments in AI, decentralized finance technologies and new-age energy solutions in companies with a market capitalization between USD 5… Login to continue reading Login…

Read MoreGlobal Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

B JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn’s disease who have… Login to continue reading Login…

Read MoreJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease